Adicet Bio (ACET) announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC. “Dosing the first patient in our Phase 1 ...
REDWOOD CITY, Calif. & BOSTON, December 19, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Adicet Bio ( (ACET)) has issued an update. Adicet Bio has initiated the Phase 1 clinical trial of ADI-270 ...
Adicet Bio (ACET) announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance ...